. 2004 Feb 23;101(9):2806–2810. doi: 10.1073/pnas.0400219101

Table 1. Oligonucleotides (presented 5′–3′).

BSPREPAFOR, CTGGAGATGGCATCAAGGGCCCCAACTGATCTTCACCAAACGTATTACC

ORIREV408, CGTAAGCCGGTACTGATTGA

TACFARUP, CAGTTGATCGGCGCGAGATT

NTERM18mer, ACATACCGTCATGCGGCCGCTGATCCTCCTCCCCC(VNN)₁₈GGCCATGGTAGATCCTGTTTC

TACFAR1, CGCCAATCAGCAACGACTGT

ORIREV108, GGGCTTTGTGGTTTCAGTTC

TACCKFOR, CAGGAAACAGGATCTACCATGACTGTGGCTGCACCATCTGTCTTC

NOTICKREV, CGTTTGGTGAAGATCAGTTGCGGCCGCTGATCCTCCTCCCCCTCCCCTGTTGAAGCTCTTTGTG

TACREV, GGTAGATCCTGTTTCCTGTGTG

V5REPAFOR, CACAGGAAACAGGATCTACCATGGCCGGAAAACCTATCCCAAACCCTCTCCTAGGACTGGATTCAACGGGGGGAGGAGGATCAGCGGCCGCAACTGATCTTCACCAAACG

ECORIGENE8, CGCCGGAATTCTTATCAGCTTGCTTTCGAGG

NOTIGENE8, CTGCAGTAATAGGCGGCCGCAGGGGGAGGAGGGTCCGCTGAGGGTGACGATCCCGCA

TACFAR2, AACGTGGCTGGCCTGGTTCA

TACFAR3, GATAAGAGACACCGGCATAC

TACFAR4, GGCGCTATCATGCCATACCG

TACFAR5, ACCATTCGGCTAGCGATGAC

TAC6, CCCCATCCCCCTGTTGACAATTAATC

NOTIRECREV, GGTGAAGATCAGTTGCGGCCGCTGATCCTCCTC

All oligonucleotides were purchased from Sigma Genosys (Pampisford, U.K.). The means of oligonucleotide purification were as follows: <35 bases, desalting; 35–50 bases, reverse-phase cartridge purification; >50 bases, PAGE purification.